Related Experiment Video
Updated: Jul 16, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Current Status of Sequential Treatment for Castration-resistant Prostate Cancer: A Retrospective Analysis
Kazuhiko Oshinomi1, Toshiki Mugita1, Tatsuki Inoue1
1Department of Urology, Showa University School of Medicine, Tokyo, Japan.
Cancer Diagnosis & Prognosis
|January 6, 2025
Summary
Androgen receptor signal inhibitors, particularly enzalutamide, are the most common first-line treatments for metastatic castration-resistant prostate cancer. Sequential treatment patterns are emerging in clinical practice.
Area of Science:
- Oncology
- Pharmacology
Background:
- Limited data exist on optimal treatment sequencing for metastatic castration-resistant prostate cancer (mCRPC).
- Understanding current drug therapy patterns in mCRPC is crucial for clinical decision-making.
Purpose of the Study:
- To investigate the current status of drug therapy for castration-resistant prostate cancer (CRPC).
- To clarify sequential treatment strategies for CRPC in actual clinical practice.
Main Methods:
- Retrospective study of 425 CRPC patients treated between 2014-2021.
- Analysis focused on the sequence of four drugs: abiraterone acetate, enzalutamide, docetaxel, and cabazitaxel.
- Treatment sequences visualized using Sankey diagrams.
Main Results:
- Androgen receptor signal inhibitors (ARSI) were the most common drug class administered (179 patients).
- Enzalutamide was the most frequent first-line drug (58.4%).
- Common second-line sequences included ARSI-ARSI (n=96) and ARSI-docetaxel (n=85).
Conclusions:
- ARSI, especially enzalutamide, dominate first-line treatment for CRPC.
- Further research is needed on patient background and prognosis related to these treatment sequences.
